Review Article

Angiogenesis and Its Therapeutic Opportunities

So Young Yoo and Sang Mo Kwon

Laboratory for Vascular Medicine and Stem Cell Biology, Convergence Stem Cell Research Center, Medical Research Institute, Pusan National University School of Medicine, Yangsan 626-870, Republic of Korea

Correspondence should be addressed to Sang Mo Kwon; smkwon323@pusan.ac.kr

Received 12 March 2013; Accepted 7 July 2013

Academic Editor: Grzegorz Szewczyk

Copyright © 2013 S. Y. Yoo and S. M. Kwon. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Angiogenesis plays critical roles in human physiology that range from reproduction and fetal growth to wound healing and tissue repair. The sophisticated multistep process is tightly regulated in a spatial and temporal manner by “on-off switch signals” between angiogenic factors, extracellular matrix components, and endothelial cells. Uncontrolled angiogenesis may lead to several angiogenic disorders, including vascular insufficiency (myocardial or critical limb ischemia) and vascular overgrowth (hemangiomas, vascularized tumors, and retinopathies). Thus, numerous therapeutic opportunities can be envisaged through the successful understanding and subsequent manipulation of angiogenesis. Here, we review the clinical implications of angiogenesis and discuss pro- and antiangiogenic agents that offer potential therapy for cancer and other angiogenic diseases.

1. Introduction

The growth of new capillaries from existing blood vessels, which is called angiogenesis, is mediated by a complex multistep process comprising a series of cellular events that lead to neovascularization [1, 2]. Angiogenesis plays a central role in various physiological processes within human body, not only during fetal development but also in tissue repair after surgery or trauma. Angiogenesis can be a hallmark of wound healing, the menstrual cycle, cancer, and various ischemic and inflammatory diseases [3–5]. The realization that tumor growth is associated with new blood vessels led us to investigate the chemical factors that mediate angiogenesis, broadened our knowledge of pathological processes, and thus opened new possibilities for the diagnosis and treatment of these diseases.

The pivotal process of angiogenesis can be simply described as multiple steps. First, angiogenic stimuli cause increased endothelial cell (EC) permeability and cellular proliferation, which continues as the new capillary sprout elongates [6]. Second, proteolysis of basement membrane matricellular components is a necessary process to promote the invasion of ECs into the stroma of the neighboring tissue [7], in which the cooperative activity of the plasminogen activator (PA) system and matrix metalloproteinases (MMPs) is required. Third, migrated ECs trigger lumen formation as the sprout forms a multicellular structure. Then, a new capillary channel is formed. Finally, the capillary is stabilized through the construction of basement membrane, adherent junctions, and ECs (Figure 1).

A number of molecules are involved in these complex angiogenic cascades. Their names and functions are described briefly in the next section and are listed in Table 1. These factors are commonly used as the targets in strategies to manipulate angiogenesis. The pathological disruption of angiogenesis can be caused by either vascular insufficiency (myocardial or critical limb ischemia) or vascular overgrowth (hemangiomas, tumors, and retinopathies) (Table 2). Thus, therapeutic benefits may be realized by manipulating angiogenesis.

2. Angiogenic Factors and Regulation of Angiogenesis

In recent decades, numerous studies focused on identifying angiogenesis stimulators, which led to the identification of several angiogenic factors. Angiogenic factors can be categorized as follows: (1) soluble growth factors such as acidic and basic fibroblast growth factor (aFGF and bFGF)
and vascular endothelial growth factor (VEGF), which are associated with EC growth and differentiation [8–10]; (2) inhibiting factors that inhibit the proliferation and enhance the differentiation of ECs, such as transforming growth factor β (TGF-β), angiogenin, and several low molecular weight substances [11–13]; and (3) extracellular matrix-bound cytokines that are released by proteolysis, which may contribute to the regulation of angiogenesis and include angio- statin, thrombospondin, and endostatin [14–18]. In addition, a number of microphages secreting bFGF, tumor necrosis factor (TNF), and VEGF were shown to be associated with tumor angiogenesis. Angiogenesis is governed by a balance between inducers and inhibitors [19]. It also can be regulated by EC proliferation, which is regulated or restrained by pericytes through the sequestration of potent mitogens in the extracellular matrix, changes in EC shape that reduce the sensitivity of the cells to growth factors, and certain endothelial integrins.

3. Angiogenic Disorders

The hypervascularity of tumors was first thought to be the inflammatory vasodilation of preexisting vessels in response to tumor metabolites and necrotic tumor products. It was also thought that tumor growth and metastasis depended on angiogenesis and that the tumor secreted the chemicals that shifted resting ECs into rapidly growing ECs. These ideas are not widely accepted yet. The concept of the role of angiogenesis in cancer and other diseases has now become clear.

3.1. Angiogenesis in Cancer. Most tumors (up to 2-3 mm³) persist in situ without neovascularization for months to years, but they become vascularized by "switches" in cells during the turnover to an angiogenic state when the tumor needs to keep growing. Cells in prevascular tumors may replicate as rapidly as those in expanding vascularized tumors; however, without the growth of new vessels, their growth is limited. A change in the local equilibrium between positive and negative angiogenic regulators of the growth of microvessels is involved in the switch to the angiogenic state [20, 21]. Of the angiogenic inducers (Table 1), those that are most commonly found in tumors appear to be VEGF and bFGF. Their angiogenic activities are synergistic [22]. VEGF plays a critical role in vasculogenesis and angiogenesis during fetal development. In a knockout mouse model, VEGF or VEGF receptor (VEGFR) inactivation resulted in defects in vasculogenesis in the early stages of development and was embryonic lethal [23].

VEGF is overexpressed in tumor stromal cells as well as tumor cells of renal cancer [24], lung cancer [25], breast cancer [26], and ovarian cancer [27]. VEGF expression is regulated positively by oncogenes such as Ras [28] and negatively by tumor suppressors such as von Hippel-Lindau (VHL) [29]. VEGF binds to VEGFR1 or VEGFR2 on the EC surface. Most of the angiogenic effects of VEGF result from VEGFR2 activation. Hypoxia is a major stimulator of VEGF expression that results from hypoxia-inducible factor 1 (HIF-1) binding to a hypoxia response element (HRE) within the VEGF promoter. It is also stimulated by inflammatory mediators (interleukin 1 (IL1), TGF-β, and

**Figure 1:** Processes in angiogenesis. (1) Angiogenic factors bind to their receptors on endothelial cells and activate the signal transduction pathways. (2) Matrix metalloproteinases are activated, and they degrade the extracellular matrix. (3) Endothelial cells migrate out of the preexisting capillary wall and proliferate. (4) Integrins are expressed by endothelial cells, facilitating their adhesion to the extracellular matrix and their migration for tube formation. (5) Angiopoietin 1 binds to Tie-2 receptors and stimulates pericyte recruitment and vessel stabilization.
Table 1: Overview of the different angiogenic factors.

| Category          | Names                                                                 | Major functions                                                                 | References |
|-------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------------------|------------|
| Proteolytic enzymes | (i) Matrix metalloproteinases (MMPs): matrilysin (MMP-7), interstitial collagenase (MMP-1), neutrophil collagenase (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), stromelysin-3 (MMP-11), metalloelastase (MMP-12), MMP-19, enamelysin (MMP-20), gelatinase A (MMP-2), gelatinase B (MMP-9), MT1-MMP (MMP-14), MT2-MMP (MMP-15), MT3-MMP (MMP-16), MT4-MMP (MMP-17)  
(ii) Plasminogen activators (PAs) | MMPs; taking different substrates according to MMPs; substrates can be collagen, gelatin, laminin, fibronectin, proteoglycans, and proMMPs | [67–69]    |
| Angiogenesis inducers | Vascular endothelial growth factor family (VEGF-A or VEGF, PIGF, VGGF-B, VEGF-C, VEGF-D, orf virus VEGF or VEGF-E), fibroblast growth factor family (aFGF, bFGF, etc.), angiopoietin 1 (Ang-1), transforming growth factor-alpha/beta (TGF α/β), platelet-derived growth factor (PDGF), hepatocyte growth factor/scatter factor (HGF/SE), tumor necrosis factor-alpha (TNFa), interleukin-1/8, angiogenin, ephrins, integrins αβ3, αβ5, α5β1, cyclooxygenase-2 (COX-2) | (i) Induction of EC proliferation, migration, and differentiation  
(ii) TGF-β shows opposite effect in some contexts | [8–10, 70–79] |
| Angiogenesis inhibitors | Thrombospondin-1/2 (TSP-1/2), angiotatin (plasminogen fragment), endostatin (collagen XVIII fragment), vasostatin (calreticulin fragment), tumstatin, platelet factor-4 (PF-4), antiangiogenic antithrombin III, kringles 5 (plasminogen fragment), prolactin 16-kD fragment, fragment of SPARC, 2-methoxyestradiol, metalloproteinase inhibitors (TIMPs), interferon-alpha/beta/gamma (IFN α/β/γ), interleukin-12 (IL-12), IP-10, Ang-2 | (i) Inhibit EC proliferation/migration  
(ii) Induce EC apoptosis  
(iii) TIMPs: inhibit MMP or uPA activity  
(iv) Ang-2: inhibit blood vessels maturation, antagonist of Ang-1 | [11–15, 18, 80–85] |

Prostaglandin E2 (PGE2)) or mechanical forces (shear stress and cell stretch). Increased PGE2 by cyclooxygenase-2 (COX-2) induces VEGF expression and angiogenesis in tumor cells or tumor stromal cells [30]. FGF signaling may be through the recruitment of other growth factor signaling pathways. The simultaneous VEGF signaling through VEGFRI was required in the bFGF-stimulated capillary organization. bFGF also initiates the transcription of hepatocyte growth factor (HGF) [31]. However, the upregulation of an angiogenic inducer is not sufficient for tumor angiogenesis. The downregulation of certain negative regulators or inhibitors (Table 1) for vessel growth may be required [21].

Tumor growth is augmented by the onset of neovascularization through a perfusion effect and a paracrine effect. The perfusion effect is more efficient at allowing nutrients and oxygen to enter and catabolites to exit in crowded tissues, and the paracrine effect results from the production of growth factors (e.g., bFGF, insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), and granulocyte colony stimulating factor (GCSF)) by ECs or their release by macrophages and other host cells that are delivered to the tumor by blood vessels. Neovascularization gradually reduces a tumor’s accessibility to chemotherapeutic drugs because tumors compress their blood supply. Antiangiogenic therapy in rodents showed increased delivery of chemotherapy agents to a tumor [32], which may be associated with lowered interstitial pressure and an unpacked mass of tumor cells.

3.2 Angiogenesis in Other Diseases. Either excessive or deficient angiogenesis can be classified as an angiogenic disease, which is an abnormal growth of microvessels (Table 2). Recent studies reported that the angiogenic protein VEGF is the chief mediator of ocular neovascularization, a major cause of blindness worldwide [33, 34]. The upregulation of VEGF is
Table 2: Clinical manipulation of angiogenesis.

| Therapeutic goal                      | Diseases                              | Definitions/symptoms                                                                 | Reference |
|---------------------------------------|---------------------------------------|--------------------------------------------------------------------------------------|-----------|
| **Hemangiomas**                       | Benign and usually a self-involuting tumor (swelling or growth) of the endothelial cells that line blood vessels and is characterised by increased number of normal or abnormal vessels filled with blood | [86]       |
| **Psoriasis**                         | Immune-mediated disease that affects the skin. The immune system mistakes a normal skin cell for a pathogen and sends out faulty signals that cause overproduction of new skin cells | [37]       |
| **Kaposi’s sarcoma**                  | Tumor caused by human herpesvirus 8 (HHV8)                                        | [87]       |
| **Ocular neovascularization**         | Abnormal or excessive formation of blood vessels in the eye                         | [88]       |
| **Inhibition of angiogenesis**        | Rheumatoid arthritis                  | Inflammatory response of the capsule around the joints (synovium), secondary to swelling (hyperplasia) of synovial cells, excess synovial fluid, and the development of fibrous tissue (pannus) in the synovium | [36]       |
|                                       | Endometriosis                         | A gynecological medical condition in which cells from the lining of the uterus (endometrium) appear and flourish outside the uterine cavity, most commonly on the membrane which lines the abdominal cavity | [89]       |
|                                       | Atherosclerosis                       | Artery wall thickens caused largely by the accumulation of macrophage white blood cells and promoted by low-density lipoproteins (LDL, plasma proteins that carry cholesterol and triglycerides) | [35]       |
|                                       | Tumor growth and metastasis           | Tumor-associated neovascularization is involved in tumor growth, invasion, and metastasis | [4]        |
| **Stimulation of angiogenesis**       | Induction of collateral vessel formation: Myocardial ischemia, Peripheral ischemia, Cerebral ischemia | After blood vessels blockage (occlusion), collateral vessels can be developed to improve blood supply to the area. | [90]       |
|                                       | Wound healing                         | Intricate process in which the skin (or another organ-tissue) repairs itself after injury. Angiogenesis occurs concurrently with fibroblast proliferation when endothelial cells migrate to the area of the wound | [91]       |
|                                       | Reconstructive surgery                | Surgery to restore the form and function of the body                                  |           |

4. Angiogenesis in Clinical Applications

Abnormal angiogenesis is the major cause of numerous diseases; therefore, angiogenesis itself can be useful for diagnostic/prognostic applications and can be manipulated for further clinical applications. In the case of ischemic diseases, which develop because of deficient angiogenesis, an angiogenesis stimulator can be used to induce therapeutic angiogenesis. In the case of cancer, which has excessive angiogenesis, angiogenic inhibitors including antiangiogenic factors can be used to attenuate angiogenesis. The Food and Drug Administration (FDA) approved becaplermin (Regranex, recombinant human PDGF-BB) for diabetic foot ulcer disease in 1977, which was the first angiogenesis-stimulating drug that was used as a therapeutic angiogenesis approach. For cancer therapeutics, the FDA approved
bevacizumab (Avastin, humanized anti-VEGF monoclonal antibody), an angiogenesis inhibitor, to treat metastatic colorectal cancer in 2004 [40].

4.1. Diagnostic and Prognostic Applications. The quantitation of angiogenesis in a biopsy specimen may help predict the risk of metastasis or recurrence. The quantitation of microvessel density in histologic specimens of invasive breast cancer, for example, has provided an indication of the risk of metastasis [41]. A positive association between tumor angiogenesis and the risk of metastasis, tumor recurrence, or death has also been reported with regard to breast cancers and other types of tumors [42–44]. A high microvessel density may be a successful predictor of metastatic risk. An increased area of the vascular surface because of a high density may facilitate the escape of cancer cells into the circulation. An angiogenic cell that is shed from a primary tumor is more likely than a nonangiogenic cell to develop into a detectable metastasis.

The quantitation of angiogenic proteins in body fluids can be used to indirectly measure angiogenic activity. Higher concentrations of bFGF were found in the serum and urine of nearly 10% and more than 37% of cancer patients, respectively [45]. Concentrations of biologically active bFGF were abnormally high in the cerebrospinal fluid of children with brain tumors but not in children with hydrocephalus or malignant disease outside the central nervous system [46].

4.2. Therapeutic Angiogenesis. Therapeutic angiogenic drugs that accelerate the angiogenesis process are useful for treating diseases of deficient angiogenesis. In preclinical studies, orally administered bFGF was shown to stimulate angiogenesis and to accelerate the healing of duodenal ulcers in rats [38]. Phase I clinical trials were then prompted to evaluate this therapy in patients with gastric or duodenal ulcers that were refractory to conventional therapy [47]. Orally administered bFGF was found to heal gastric ulcers that were caused by nonsteroidal anti-inflammatory drugs. Orally administered aFGF induced angiogenesis in the ulcer bed and accelerated the healing of ulcers in animals [38].

A phase I clinical trial of therapeutic angiogenesis using bFGF protein in heparin-alginate slow-release microcapsules in 8 patients with symptomatic, severe coronary artery disease that was not amenable to complete revascularization by either percutaneous transluminal coronary angioplasty or coronary artery bypass grafting demonstrated the feasibility and safety of bFGF administration for coronary artery diseases [48]. These clinical studies suggest that angiogenic and other growth factors can heal gastrointestinal ulceration as well as coronary artery diseases. It is interesting to note that the antiulcer drug sucralfate (sucrose aluminum sulfate or Carafate) appears to act by protecting endogenous mucosal bFGF from degradation by acid.

Angiogenic agents can be used in ischemic heart disease as a therapeutic angiogenesis approach for cardiac tissue repair and regeneration [49, 50]. The therapeutic goal of this condition is to stimulate angiogenesis to improve perfusion, deliver survival factors to sites of tissue repair, mobilize regenerative stem cell populations, and ultimately restore form and function to the tissue. Although more than 2,000 patients with heart disease have received some form of experimental angiogenic therapy [51, 52], currently there are no FDA-approved angiogenic drugs to treat ischemic cardiovascular disease. The first FDA-approved device to stimulate new blood vessel growth in diseased hearts is a laser that is used in a technique called direct myocardial revascularization (DMR) or transmyocardial revascularization (TMR).

5. Antiangiogenic Therapies

Many studies using ECs that were isolated from either capillaries or large vessels led to considerable insights into the molecular and cellular biology of angiogenesis and the discovery and evaluation of potential antiangiogenic compounds (Table 3). They were identified using classical angiogenesis assays such as the chick chorioallantoic membrane (CAM), rabbit cornea assay, sponge implant models, and matrigel plugs [53–57]. Recent research has focused on the specific effects of antiangiogenic compounds on individual angiogenic processes. In this section, we discuss their clinical applications as antiangiogenic therapies.

5.1. Interferon Alpha-2a to Treat Hemangiomas. Heman giomas occur in 1 out of 100 neonates and in 1 out of 5 premature infants [58]. Most do not need treatment because these tumors grow rapidly in the first year of life (the proliferating phase), slow down during the next 5 years (the involuting phase), and gradually regress by the age of 10–15 years (the involuted phase). However, about 10% of them may have serious tissue damage that includes interfering with a vital organ, obstructive airway, heart failure, or Kasabach-Merritt syndrome. Kasabach-Merritt syndrome, a platelet-trapping thrombocytopenic coagulopathy, and hepatic hemangiomas have a mortality rate of 30%–50%. Corticosteroid therapy worked for 30% of hemangiomas [59]. Radiation, cyclophosphamide treatment, and embolization were also tried and showed favorable outcomes; however, sometimes they showed toxicity. Interferon alpha-2a (IFNα-2a) is an angiogenic agent that could be useful for treating these hemangiomas. It was successfully used in a 7-year-old child with pulmonary hemangiomas [60]. It was also found that therapy with IFNα-2a accelerated the tumor regression in 18 of 20 hemangioma patients [61]. IFNα-2a suppresses the production of FGFs in human tumor cells, which could work for hemangiomas because bFGF is an angiogenic factor that is overexpressed in hemangiomas.

5.2. Ocular Neovascularization. Ophthalmology angiogenesis in the eye, an ocular neovascularization, includes age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), neovascular glaucoma, corneal neovascularization (trachoma), and pterygium. Inhibiting VEGF is presently an antiangiogenic therapy that is approved for ophthalmic conditions. Two currently approved antiangiogenic therapies for ophthalmic diseases are an anti-VEGF aptamer (pegaptanib, Macugen) and a Fab fragment of a monoclonal antibody directed against


**Table 3: Antiangiogenic compounds and their mechanism of action (adapted from references [2, 92–102]).**

| Inhibiting angiogenic process | Antiangiogenic compounds | Mechanism of action |
|------------------------------|--------------------------|---------------------|
| **Inhibitors of ECM remodeling** | Batimastat, Marimastat, AG3340, Neovastat, PEX, TIMP-1,2,3,4 PAI-1,2, uPA Ab, uPAR Ab, Amiloride Minocycline, tetracyclines, cartilage-derived TIMP | MMP inhibitors, block endothelial and tumor cell invasion uPA inhibitors, block ECM breakdown Collagenase inhibitors, disrupt collagen synthesis and deposition |
| **Inhibitors of adhesion molecules** | $\alpha_\beta_3$ Ab: LM609 and Vitaxin, RGD containing peptides, $\alpha_\beta_3$ Ab Benzodiazepine derivatives | Block EC adhesion, induce EC apoptosis Antagonist of $\alpha_\beta_3$ |
| **Inhibitors of activated ECs** | Endogenous inhibitors: endostatin, angiostatin, aaAT IFN-α, IFN-γ, IL-12, nitric oxide synthase inhibitors, TSP-1 TNP-470, Combretastatin A-4 Thalidomide Linomide | Block EC proliferation, induce EC apoptosis, inhibit angiogenic switch Block EC migration and/or proliferation Inhibits angiogenesis in vivo Inhibits EC migration |
| **Inhibitors of angiogenic inducers or their receptors** | IFN-α, PF-4, prolactin fragment Suramin and analogues | Inhibit bFGF, Inhibit bFGF-induced EC proliferation Bind to various growth factors including bFGF, VEGF, PDGF, inhibit EC migration and proliferation |
| | PPS, distamycin A analogues, bFGF Ab, antisense-bFGF Protamine | Inhibit bFGF activity Binds heparin, inhibits EC migration and proliferation |
| | SU5416, soluble Flt-1, dominant-negative Flk-1, VEGF receptor, ribozymes, VEGF Ab Aspirin, NS-398 6AT, 6A5BU, 7-DX | Block VEGF activity COX inhibitors TP antagonists |
| **Inhibitors of EC intracellular signaling** | Genistein Lavendustin A Ang-2 | Tyrosine kinase inhibitor, blocks uPA, EC migration and proliferation Selective inhibitor of protein tyrosine kinase Inhibits Tie-2 |

VEGF (ranibizumab, Lucentis). A photodynamic therapy called Visudyne (QLT Therapeutics/CIBA Vision) has shown effectiveness for treating macular degeneration and was the first FDA-approved blood vessel therapy for eye disease in 2004 [62, 63].

5.3. **Rheumatoid Arthritis.** Clinical trials of angiogenic inhibitors have not been performed yet in patients with arthritis; however, minocycline and TNP-470 (also known as AGM-470) have shown efficacy as potent inhibitors of the vascular pannus in experimental arthritis [36, 64].

5.4. **Cancer.** Angiogenesis plays a critical role in the growth and spread of cancer because a blood supply is necessary for tumor growth and metastases. Tumors secrete chemical signals that stimulate angiogenesis and thus stimulate nearby normal cells. Therefore, many natural or synthetic angiogenesis inhibitors, also called antiangiogenic agents, have been studied to prevent or slow the growth of cancer. These inhibitors can interfere with angiogenesis in various ways. Bevacizumab (Avastin) is a monoclonal antibody that specifically recognizes and binds to VEGF, which prevents VEGF from activating VEGFR [40]. In contrast, other angiogenesis inhibitors, including sorafenib and sunitinib, bind to receptors on the ECs or to other proteins in the downstream signaling pathways to block their activities [65].

Bevacizumab was FDA-approved to be used alone to treat glioblastoma and to be used in combination with other drugs to treat metastatic colorectal cancer, some nonsmall cell lung cancers, and metastatic renal cell cancer. Bevacizumab is the first approved angiogenesis inhibitor that was shown to slow tumor growth and, more importantly, to extend the lives of patients with some cancers. The other FDA-approved antiangiogenic drugs are sorafenib (Nexavar) for hepatocellular carcinoma and kidney cancer, sunitinib (Sutent) for kidney cancer and neuroendocrine tumors, pazopanib (Votrient) for kidney cancer and neuroendocrine tumors, and everolimus
### Table 4: Selected angiogenesis inhibitors in clinical trials.

| Inhibiting target                             | Drug                        | Sponsor                          | Clinical trials/mechanism                                                                 | References |
|-----------------------------------------------|-----------------------------|----------------------------------|------------------------------------------------------------------------------------------|------------|
| Epidermal growth factor receptor (EGFR)       | Gefitinib (Iressa)          | AstraZeneca and Teva             | FDA-approved in 2003 for NSCLC/effective in cancers with mutated and overactive EGFR     | [103, 104] |
|                                               | Lapatinib (Tykerb)          | GSK                              | FDA-approved in 2007 for breast cancer/dual tyrosine kinase inhibitor which interrupts the  | [105]      |
|                                               |                             |                                  | HER2/neu and epidermal growth factor receptor (EGFR) pathways                           |            |
|                                               | Erlotinib (Tarceva)         | Genentech/OSI pharmaceuticals/Roche| FDA-approved in 2005/used to treat nonsmall cell lung cancer, pancreatic cancer, and several   | [106]      |
|                                               | Canertinib (CI-1033)        | Selleck Chemicals                | Phase II/irreversible tyrosine-kinase inhibitor with activity against EGFR, HER-2, and ErB-4 | [107]      |
| VEGFR                                         | Vatalanib (PTK787 or PTK/ZK)| Bayer Schering and Novartis      | Phase III/it inhibits all known VEGF receptors, as well as platelet-derived growth factor    | [108]      |
| VEGFR-2                                       | IMC-1C1                     | ImClone Systems                  | Phase I/chimerized monoclonal antibody                                                    | [109]      |
| VEGFR-3                                       | mF4-3IC1                     | ImClone Systems                  | Phase I/rat monoclonal antibody to murine VEGFR-3, which potently antagonizes the binding   | [110]      |
|                                               |                             |                                  | of VEGF-C to VEGF-3                                                                      |            |
| Multiple growth factor receptors               | Imatinib (Glivec)           | Novartis                         | FDA-approved in 2001/competitive tyrosine-kinase inhibitor used in the treatment of multiple  | [111]      |
|                                               | Sunitinib (Sutent)          | Pfizer                           | chromosone-positive (Ph+) chronic myelogenous leukemia (CML)                              |            |
|                                               |                             |                                  | FDA-approved in 2006 for renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal  |            |
|                                               |                             |                                  | stromal tumor (GIST)/the simultaneous inhibition of receptors for platelet-derived growth    |            |
|                                               |                             |                                  | factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs)                  |            |
|                                               | Sorafenib (Nexavar)         | Bayer and Onyx pharmaceuticals    | FDA-approved in 2005/a small molecular inhibitor of several tyrosine protein kinases       | [112]      |
|                                               |                             |                                  | (VEGFR and PDGFR) and Raf kinases (more avidly C-Raf than B-Raf)                           |            |
|                                               | Pazopanib (Votrient)        | GlaxoSmithKline                  | FDA-approved in 2009 for advanced renal cancer/multitargeted receptor tyrosine kinase      | [113]      |
|                                               |                             |                                  | inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α/β, and c-kit                               |            |
| VEGF                                          | Bevacizumab (Avastin)        | Genentech/Roche                  | FDA-approved in 2004 for metastatic colorectal cancer/humanized anti-VEGF mAb, licensed to  | [114]      |
|                                               |                             |                                  | treat various cancers including colorectal, lung, breast (outside the USA), glioblastoma (USA |            |
|                                               |                             |                                  | only), kidney, and ovarian                                                               |            |
| Integrin αvβ3                                 | Vitaxin                     | Applied molecular evolution       | Phase II as a treatment for colorectal cancer/humanized monoclonal antibody against the    | [115, 116] |
|                                               |                             |                                  | vascular integrin αvβ3                                                                  |            |

Researchers are exploring the use of angiogenesis inhibitors in some clinical trials (Table 4).

5.5. Conventional Anticancer Therapy versus Antiangiogenic Therapy. Conventional anticancer therapy generally faces the problems of drug resistance and impaired drug delivery because of genomic instability and the tumor mass of cancers [66]. Tumor mass has an interstitium composed of a collagen-rich matrix between cancer cells and vascular cells. Anticancer drugs need to pass through the interstitium from blood vessels to reach the cancer cells. However, tumor mass has an interstitium with an abnormally high interstitial fluid pressure, which acts as a barrier to drug delivery. However, angiogenesis inhibitors inhibit the growth of blood vessels rather than tumor cells. In some cancers, angiogenesis inhibitors are most effective when they are combined with additional therapies, especially chemotherapy. It has been
hypothesized that these drugs help normalize the blood vessels that supply the tumor, facilitating the delivery of other anticancer agents [32]. Angiogenesis inhibitor therapy may prevent tumor growth instead of killing tumors. Therefore, antiangiogenic therapy may require a long period for treatment.

6. Concluding Remarks and Prospects

Currently, chemotherapeutic drugs are being used to treat cancer as well as other diseases. Unfortunately, many compounds showed limited efficacy with impaired delivery, penetration, and selectivity for the tumor cells, thereby causing serious side effects and bystander effects. The activity of these compounds is mainly restricted by the drug resistance of tumor cells. Preclinical studies and clinical trials suggest that angiogenesis-based therapy may be useful in the future care of patients. In particular, antiangiogenic therapy is a unique approach to kill tumor cells because it does not directly target cancer cells; instead, it inhibits the growth of blood vessels. So far, antiangiogenic agents are not likely to result in bone marrow suppression, gastrointestinal symptoms, or hair loss. The approach to slow the growth of blood vessels may require several months to a year; thus, the administration of the agents at lower doses and longer uninterrupted periods than the usual doses and periods of conventional cytotoxic agents should be considered in the design of clinical trials. The development of resistance to angiogenic inhibitors has not been a big problem so far. Furthermore, a combination of antiangiogenic therapy and conventional therapy may be more effective than either therapy alone. Angiogenesis-based therapy may provide a novel, selective, safe, and reasonable treatment in future medicine.

Conflict of Interests

The authors declare that there is no conflict of interests.

Acknowledgment

This work was supported by Grants from the National Research Foundation funded by the Korean government (MEST: 2010-0020260, 20120618, 2012M3A9C6049720; MSIFP: 2013R1A1A3008484).

References

[1] J. Folkman, “Clinical applications of research on angiogenesis,” The New England Journal of Medicine, vol. 333, no. 26, pp. 1757–1763, 1995.
[2] M. Klagsbrun and M. A. Moses, “Molecular angiogenesis,” Chemistry and Biology, vol. 6, no. 8, pp. R217–R224, 1999.
[3] J. Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,” Nature Medicine, vol. 1, no. 1, pp. 27–31, 1995.
[4] J. M. Pluda, “Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies,” Seminars in Oncology, vol. 24, no. 2, pp. 203–218, 1997.
[5] C. G. Colpaert, P. B. Vermeulen, I. Benoy et al., “Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression,” British Journal of Cancer, vol. 88, no. 5, pp. 718–725, 2003.
[6] M. S. Pepper, “Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 7, pp. 1104–1117, 2001.
[7] P. Mignatti and D. B. Rifkin, “Plasminogen activators and matrix metalloproteinases in angiogenesis,” Enzyme and Protein, vol. 49, no. 1–3, pp. 117–137, 1996.
[8] W. H. Burgess and T. Maciag, “The heparin-binding (fibroblast) growth factor family of proteins,” Annual Review of Biochemistry, vol. 58, pp. 575–602, 1989.
[9] G. Conn, M. L. Bayne, D. D. Soderman et al., “Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3549–580, 2004.
[10] A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. van Oosterom, and E. A. De Bruijn, “Vascular endothelial growth factor and angiogenesis,” Pharmacological Reviews, vol. 56, no. 4, pp. 549–580, 2004.
[11] M. A. Sovak, M. Arusga, G. Zanieski, K. T. Kavanagh, and G. E. Sonenshein, “The inhibitory effects of transforming growth factor β on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-kB/Rel expression,” Cell Growth and Differentiation, vol. 10, no. 8, pp. 537–544, 1999.
[12] A. B. Roberts and M. B. Sporn, “Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-β,” American Review of Respiratory Disease, vol. 140, no. 4, pp. 1126–1128, 1989.
[13] J. Folkman and M. Klagsbrun, “Angiogenic factors,” Science, vol. 235, no. 4787, pp. 442–447, 1987.
[14] K. Norrbry, “Mast cells and angiogenesis: review article,” APMIS, vol. 110, no. 5, pp. 355–371, 2002.
[15] M. S. O’Reilly, L. Holmgren, Y. Shing et al., “Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma,” Cell, vol. 79, no. 2, pp. 315–328, 1994.
[16] S. Gately, P. Twardowski, M. S. Stack et al., “Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin,” Cancer Research, vol. 56, no. 21, pp. 4887–4890, 1996.
[17] L. A. DiPietro and P. J. Polverini, “Angiogenic macrophages produce the angiogenic inhibitor thrombospondin-I,” American Journal of Pathology, vol. 143, no. 3, pp. 678–684, 1993.
[18] M. S. O’Reilly, T. Boehm, Y. Shing et al., “Endostatin: an endothe- nous inhibitor of angiogenesis and tumor growth,” Cell, vol. 88, no. 2, pp. 277–285, 1997.
[19] M. S. O’Reilly, L. Holmgren, Y. Shing et al., “Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma,” Cell, vol. 79, no. 2, pp. 315–328, 1994.
[20] L. Holmgren, M. S. O’Reilly, and J. Folkman, “Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression,” Nature Medicine, vol. 1, no. 2, pp. 149–153, 1995.
[21] K. M. Dameron, O. V. Volpert, M. A. Tainsky, and N. Bouck, “Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-I,” Science, vol. 265, no. 5178, pp. 1582–1584, 1994.
[22] M. S. Pepper, N. Ferrara, L. Orci, and R. Montesano, “Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro,” Biochemical and Biophysical Research Communications, vol. 189, no. 2, pp. 824–831, 1992.

[23] N. Ferrara, K. Carver-Moore, H. Chen et al., “Heterozygous embryonic lethality induced by targeted inactivation of the VEGf gene,” Nature, vol. 380, no. 6573, pp. 439–442, 1996.

[24] M. Tomisawa, T. Tokunaga, Y. Oshika et al., “Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma,” European Journal of Cancer, vol. 35, no. 1, pp. 133–137, 1999.

[25] M. Volm, R. Koomägi, and J. Mattern, “Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer,” International Journal of Cancer, vol. 74, no. 1, pp. 64–68, 1997.

[26] H. Yoshiji, D. E. Gomez, M. Shibuya, and U. P. Thorgeirsson, “Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer,” Cancer Research, vol. 56, no. 9, pp. 2013–2016, 1996.

[27] H. M. Sowter, A. N. Corps, A. L. Evans, D. E. Clark, D. S. Charnock-Jones, and S. K. Smith, “Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors,” Laboratory Investigation, vol. 77, no. 6, pp. 607–617, 1997.

[28] F. Okada, J. W. Rak, B. S. Croix et al., “Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 7, pp. 3609–3614, 1998.

[29] O. Iliopoulos, A. P. Levy, C. Jiang, W. G. Kaelin Jr., and M. A. Goldberg, “Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 20, pp. 10595–10599, 1996.

[30] H. Seno, M. Oshima, T.-O. Ishikawa et al., “Cyclooxygenase 2- and prostaglandin E2 receptor EP2-dependent angiogenesis in ApCa716 mouse intestinal polyps,” Cancer Research, vol. 62, no. 2, pp. 506–511, 2002.

[31] M. Onimaru, Y. Yonemitsu, M. Tanii et al., “Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs,” Circulation Research, vol. 91, no. 10, pp. 923–930, 2002.

[32] B. A. Teicher, S. A. Holden, G. Ara et al., “Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents,” International Journal of Cancer, vol. 57, no. 6, pp. 920–925, 1994.

[33] J. W. Miller, A. P. Adams, D. T. Shima et al., “Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model,” American Journal of Pathology, vol. 145, no. 3, pp. 574–584, 1994.

[34] L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” The New England Journal of Medicine, vol. 331, no. 22, pp. 1480–1487, 1994.

[35] E. R. O’Brien, M. R. Garvin, R. Dev et al., “Angiogenesis in human coronary atherosclerotic plaques,” American Journal of Pathology, vol. 145, no. 4, pp. 883–894, 1994.

[36] D. J. Peacock, M. L. Banquero, and E. Brahn, “Angiogenesis inhibition suppresses collagen arthritis,” Journal of Experimental Medicine, vol. 175, no. 4, pp. 1135–1138, 1992.

[37] B. J. Nickoloff, R. S. Mitra, J. Varani, V. M. Dixit, and P. J. Polverini, “Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis,” American Journal of Pathology, vol. 144, no. 4, pp. 820–828, 1994.

[38] J. Folkman, S. Szabo, M. Stovroff, P. McNeil, W. Li, and Y. Shing, “Duodenal ulcer: discovery of a new mechanism and development of angiogenic therapy that accelerates healing,” Annals of Surgery, vol. 214, no. 4, pp. 414–427, 1991.

[39] B. Gontijo, L. B. Pereira, and C. M. R. Silva, “Vascular malformations,” Anais Brasileiros de Dermatologia, vol. 79, no. 1, pp. 7–25, 2004.

[40] T. Shih and C. Lindley, “Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies,” Clinical Therapeutics, vol. 28, no. 11, pp. 1779–1802, 2006.

[41] N. Weidner, J. P. Semple, W. R. Welch, and J. Folkman, “Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma,” The New England Journal of Medicine, vol. 324, no. 1, pp. 1–8, 1991.

[42] R. Vang, F. A. Tavassoli, A. Shaaban, and C. S. Foster, “Risk for subsequent development of breast cancer,” American Journal of Surgical Pathology, vol. 27, no. 2, pp. 268–274, 2003.

[43] J. P. Dales, S. Garcia, S. Carpentier et al., “Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression,” Human Pathology, vol. 35, no. 2, pp. 176–183, 2004.

[44] K. Sfiridaki, C. A. Pappa, G. Tsiarakis et al., “Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment,” Mediators of Inflammation, vol. 2011, Article ID 867576, 7 pages, 2011.

[45] M. Nguyen, H. Watanabe, A. E. Budson, J. P. Richie, D. F. Hayes, and J. Folkman, “Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers,” Journal of the National Cancer Institute, vol. 86, no. 5, pp. 356–361, 1994.

[46] V. W. Li, R. D. Folkerton, H. Watanabe et al., “Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours,” The Lancet, vol. 344, no. 8915, pp. 82–86, 1994.

[47] M. A. Hull, D. J. E. Cullen, N. Hudson, and C. J. Hawkey, “Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration,” Gut, vol. 37, no. 5, pp. 610–612, 1995.

[48] F. W. Selke, R. J. Laham, E. R. Edelman, J. D. Pearlman, and M. Simons, “Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results,” Annals of Thoracic Surgery, vol. 65, no. 6, pp. 1540–1544, 1998.

[49] W. W. Li, K. E. Talcott, A. W. Zhai, E. A. Kruger, and V. W. Li, “The role of therapeutic angiogenesis in tissue repair and regeneration,” Advances in Skin & Wound Care, vol. 18, no. 9, pp. 491–502, 2005.

[50] S.-W. Lee, J.-Y. Won, H.-Y. Lee et al., “Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardial integrin-β1/ERK/caspase-9
Mediators of Inflammation

[86] A. N. Haggstrom, B. A. Drolet, E. Baselga et al., “Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment,” *Pediatrics*, vol. 118, no. 3, pp. 882–887, 2006.

[87] K. Kaposi, “Idiopathisches multiples Pigmentsarkom der Haut,” *Archiv für Dermatologie und Syphilis*, vol. 4, no. 2, pp. 265–273, 1872.

[88] K. A. Neely and T. W. Gardner, “Ucular neovascularization: clarifying complex interactions,” *American Journal of Pathology*, vol. 153, no. 3, pp. 665–670, 1998.

[89] C. L. Pearce, C. Templeman, M. A. Rossing et al., “Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies,” *The Lancet Oncology*, vol. 13, no. 4, pp. 385–394, 2012.

[90] M. Fernandez, F. Vizzutti, J. C. Garcia-Pagan, J. Rodes, and J. Bosch, “Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice,” *Gastroenterology*, vol. 126, no. 3, pp. 886–894, 2004.

[91] P. Martin, “Wound healing—aiming for perfect skin regeneration,” *Science*, vol. 276, no. 5309, pp. 75–81, 1997.

[92] S. Liekens, E. de Clercq, and J. Neyts, “Angiogenesis: regulators and clinical applications,” *Biochemical Pharmacology*, vol. 61, no. 3, pp. 253–270, 2001.

[93] G. Gasparini, “The rationale and future potential of angiogenesis inhibitors in neoplasia,” *Drugs*, vol. 58, no. 1, pp. 17–38, 1999.

[94] V. Brower, “Tumor angiogenesis—new drugs on the block,” *Nature Biotechnology*, vol. 2-3, pp. 169–193, 1999.

[95] V. Cea, C. Sala, and C. Verpelli, “Antiangiogenic therapy for glioma,” *Journal of Signal Transduction*, vol. 2010, Article ID 546826, 14 pages, 2010.

[96] A. N. Haggstrom, B. A. Drolet, E. Baselga et al., “Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment,” *Pediatrics*, vol. 118, no. 3, pp. 882–887, 2006.

[97] H.-C. Wu, C.-T. Huang, and D.-K. Chang, “Anti-angiogenic therapeutic drugs for treatment of human cancer,” *Journal of Cancer Molecules*, vol. 4, no. 2, pp. 37–45, 2008.

[98] H. G. Augustin, “Antiangiogenic tumour therapy: will it work?” *Trends in Pharmacological Sciences*, vol. 19, no. 6, pp. 216–222, 1998.

[99] T.-P. D. Fan, R. Jaggar, and R. Bicknell, “Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy,” *Trends in Pharmacological Sciences*, vol. 16, no. 2, pp. 57–66, 1995.

[100] J. M. Hamby and H. D. H. Shalowalter, “Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors,” *Pharmacology and Therapeutics*, vol. 82, no. 2-3, pp. 169–193, 1999.

[101] S. J. Shiff and B. Rigas, “Aspirin for cancer,” *Nature Medicine*, vol. 5, no. 12, pp. 1348–1349, 1999.

[102] F. Parmegiani, C. Campa, C. Costagliola et al., “Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications,” *Mediators of Inflammation*, vol. 2010, Article ID 546826, 14 pages, 2010.

[103] W. Pao, V. Miller, M. Zakowski et al., “EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 36, pp. 13306–13311, 2004.

[104] M. H. Cohen, G. A. Williams, R. Srithara, G. Chen, and R. Pazdur, “FDA drug approval summary: gefitinib (ZD1839) (Iressa®) tablets,” *Oncologist*, vol. 8, no. 4, pp. 303–306, 2003.

[105] B. Moy, P. Kirkpatrick, S. Kar, and P. Goss, “Lapatinib,” *Nature Reviews Drug Discovery*, vol. 6, no. 6, pp. 431–432, 2007.

[106] M. H. Cohen, J. R. Johnson, Y.-F. Chen, R. Srithara, and R. Pazdur, “FDA drug approval summary: erlotinib (Tarceva®) tablets,” *Oncologist*, vol. 10, no. 7, pp. 461–466, 2005.

[107] P. A. Jänner, J. Von Pawel, R. B. Cohen et al., “Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer,” *Journal of Clinical Oncology*, vol. 25, no. 25, pp. 3936–3944, 2007.

[108] M. Los, J. M. L. Roodhart, and E. E. Voest, “Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer,” *Oncologist*, vol. 12, no. 4, pp. 443–450, 2007.

[109] J. A. Posey, T. C. Ng, B. Yang et al., “A phase I study of anti-angiogenes insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma,” *Clinical Cancer Research*, vol. 9, no. 4, pp. 1323–1332, 2003.

[110] B. Pytowski, J. Goldman, K. Persaud et al., “Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody,” *Journal of the National Cancer Institute*, vol. 97, no. 1, pp. 14–21, 2005.

[111] M. Habeck, “FDA licences imatinib mesylate for CML,” *The Lancet Oncology*, vol. 3, no. 1, p. 6, 2002.

[112] E. P. Rock, V. Goodman, J. X. Jiang et al., “Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma,” *Oncologist*, vol. 12, no. 1, pp. 107–113, 2007.

[113] L. Lang, “FDA approves sorafenib for patients with inoperable liver cancer,” *Gastroenterology*, vol. 134, no. 2, p. 379, 2008.

[114] G. Sonpave, T. E. Hutsen, and C. N. Sternberg, “Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma,” *Expert Opinion on Investigational Drugs*, vol. 17, no. 2, pp. 253–261, 2008.

[115] S. Sleijfer, I. Ray-Coquard, Z. Papai et al., “Pazopanib, a multitkiine angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 62043),” *Journal of Clinical Oncology*, vol. 27, no. 19, pp. 3126–3132, 2009.

[116] A. Sandler, R. Herbst, P. Bunn et al., “Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways,” *Clinical Cancer Research*, vol. 12, no. 14, pp. 4421s–4425s, 2006.

[117] D. G. McNeel, J. Eckhoff, F. T. Lee et al., “Phase I trial of a monoclonal antibody specific for α v β3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion,” *Clinical Cancer Research*, vol. 11, no. 21, pp. 7851–7860, 2005.